The primary outcome listed of the current mCRC tri
Post# of 158771
(Total Views: 653)
Posted On: 11/06/2025 12:51:23 PM
The primary outcome listed of the current mCRC trial is ORR
"Efficacy will be measured as the effect on objective response rate (ORR) of leronlimab when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, refractory, MSS, mCRC.
ORR is defined as the proportion of subjects with the best overall response (BOR) or confirmed CR or confirmed PR according to RECIST version 1.1."
https://clinicaltrials.gov/study/NCT06699836?...study-plan
However, I believe they are measuring the PD-L1 levels throughout which could impact.
"Efficacy will be measured as the effect on objective response rate (ORR) of leronlimab when used in combination with trifluridine and tipiracil + bevacizumab in patients with CCR5+, refractory, MSS, mCRC.
ORR is defined as the proportion of subjects with the best overall response (BOR) or confirmed CR or confirmed PR according to RECIST version 1.1."
https://clinicaltrials.gov/study/NCT06699836?...study-plan
However, I believe they are measuring the PD-L1 levels throughout which could impact.
(5)
(0)CytoDyn Inc (CYDY) Stock Research Links
There are no guarantees in investing. No one should consider these pages or posts to be financial advice. Everyone has a responsibility to verify and thoroughly learn more than what is referenced or written here, and everyone must take responsibility for their own investing decisions.